Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 148

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 148
---
 of U.S. 8,455,636, which previously was involved in U.S. Patent Interference No. 106,007. (Judgment dated April 29, 2016 ordered cancellation of (i) all claims, except claim 77, of U.S. Application No. 11/233,495 to BioMarin (AZL); and (ii) U.S. 8,455,636 to us (UWA). Appeal by BioMarin (AZL) to the Court of Appeals for the Federal Circuit (Case No. 2016-2262) voluntarily dismissed July 27, 2017.)

2.Involved in Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc., C.A. No. 21-1015 (LPS) (D. Del. 2021).

In connection with its FDA approval on December 12, 2019, the FDA granted VYONDYS 53 (golodirsen) Orphan Drug Exclusivity until December 12, 2026.

Casimersen 

    Patent Number 
    Country/Region
    Patent Type
    Expiration Date**
    Owner/Licensor 

    U.S. 9,447,415
    United States
    Composition of Matter
    June 28, 2025
    UWA

    U.S. RE48,9601
    United States
    Compositions of Matter & Methods of Use
    June 28, 2025
    UWA

    U.S. 9,228,187
    United States
    Composition of Matter
    November 12, 2030
    UWA

    U.S. 9,758,783
    United States
    Methods of Use
    November 12, 2030
    UWA

    U.S. 10,287,586
    United States
    Composition of Matter
    November 12, 2030
    UWA

    U.S. 10,781,450
    United States
    Methods of Use
    November 12, 2030
    UWA

-17-

    EP 2 499 249 B1
    Europe
    Composition of Matter & Methods of Use
    November 12, 2030
    UWA

1.Reissue of U.S. 8,524,880.

In connection with